| 1.54 0 (0%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.89 | 1-year : | 2 |
| Resists | First : | 1.62 | Second : | 1.72 |
| Pivot price | 1.54  |
|||
| Supports | First : | 1.47 | Second : | 1.22 |
| MAs | MA(5) : | 1.52 |
MA(20) : | 1.54 |
| MA(100) : | 1.57 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.3 |
D(3) : | 23.5 |
| RSI | RSI(14): 47.2 | |||
| 52-week | High : | 2.66 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CGEN ] has closed above bottom band by 48.9%. Bollinger Bands are 38.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.55 - 1.56 | 1.56 - 1.56 |
| Low: | 1.48 - 1.49 | 1.49 - 1.49 |
| Close: | 1.53 - 1.54 | 1.54 - 1.55 |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Wed, 17 Dec 2025
Cancer immunotherapy royalty deal brings biotech up to $90M in funding - Stock Titan
Wed, 17 Dec 2025
Compugen rises on royalty deal with AstraZeneca (CGEN:NASDAQ) - Seeking Alpha
Wed, 12 Nov 2025
Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Mon, 10 Nov 2025
Earnings call transcript: Compugen Q3 2025 sees revenue miss, stock rises - Investing.com
Fri, 07 Nov 2025
Compugen Ltd expected to post a loss of 9 cents a share - Earnings Preview - TradingView — Track All Markets
Fri, 07 Nov 2025
Compugen Ltd (CGEN) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 13.6 (%) |
| Shares Short | 909 (K) |
| Shares Short P.Month | 954 (K) |
| EPS | -0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.46 |
| Profit Margin | 0 % |
| Operating Margin | -417.4 % |
| Return on Assets (ttm) | -18.2 % |
| Return on Equity (ttm) | -53 % |
| Qtrly Rev. Growth | -89 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -5.14 |
| PEG Ratio | 0 |
| Price to Book value | 3.27 |
| Price to Sales | 20.87 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|